Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Exelixis' Strong Cabometyx Start Signals Changing Of Guard In Kidney Cancer Market

Executive Summary

One of a trio of new drugs shaking up the kidney cancer market, Cabometyx (cabozantinib) does better than expected in its first nine weeks on the US market, and additional indications are on the near horizon.

Advertisement

Related Content

Exelixis's CABOSUN Rises For Cabometyx After Bristol's Opdivo/Yervoy Letdown
Immuno-Oncology Outlook: Pfizer's Inlyta Fits Well In Combos For Kidney Cancer
Exelixis Makes The Case For Early Filing Of Cabozantinib In Frontline Kidney Cancer
Exelixis Hopes CABOSUN Means New Dawn For Cabometyx In Frontline Kidney Cancer
ESMO Preview: Opdivo Under Pressure
Kidney Cancer Gets A Double Uplift From Latest CHMP Meeting
Value Measures, Side Effects Help Differentiate Drugs In Crowded Kidney Cancer Market

Topics

Related Companies

Related Deals

Advertisement
UsernamePublicRestriction

Register

SC097063

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

All set! This Question has been sent to my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel